Kiora Pharmaceuticals, Inc. KPRX
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -20.81%
- 1 year
- -38.82%
- Open
- 1.78
- Prev close
- 1.76
- Mkt cap
- 6.90M
- Vol
- 100.69K
- Avg vol
- 24.41K
- EPS
- -2.46
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.55
- High
- 1.83
- Forward P/E
- -1.48
- Beta
- -0.29
- Short ratio
- 0.27
- Inst. own
- 48.34%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 28, 2024
- 50-d avg
- 3.47
- 200-d avg
- 4.14
- 1y target
- 40.50
3M chart
Signals (20)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 29, 2026 | 3 days ago |
| RSI: Oversold | Oct 23, 2026 | 1 week ago |
| SMA: Bearish | Sep 29, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 29, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 14, 2026 | 1 month ago |
| SMA: Bullish | Sep 10, 2026 | 1 month ago |
| SMA: Bearish | Sep 3, 2026 | 1 month ago |
| SMA: Bearish | Sep 3, 2026 | 1 month ago |
| SMA: Bullish | Sep 2, 2026 | 2 months ago |
| SMA: Bullish | Sep 2, 2026 | 2 months ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| SMA: Bullish | Aug 17, 2026 | 2 months ago |
| SMA: Bearish | Aug 14, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
| SMA: Bullish | Aug 6, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 6, 2026 | 2 months ago |
| SMA: Bearish | Aug 4, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 4, 2026 | 2 months ago |
Key statistics
- Market cap
- 9.87M
- Enterprise value
- -17.14M
- Trailing P/E
- 3.13
- Forward P/E
- -1.48
- PEG ratio
- 0.00
- Price / sales
- 0.62
- Price / book
- 0.46
- EPS (TTM)
- 1.05
- Beta
- -0.29
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 19.98%
- Revenue (TTM)
- 16.02M
- Revenue growth
- 0.00%
- Free cash flow
- 1.47M
- Total cash
- 27.82M
- Total debt
- 82.32K
- Return on equity
- 13.69%
- Shares outstanding
- 3.00M
- Short % of float
- 0.12%
- 50-day average
- 3.47
- 200-day average
- 4.14
Analyst view
Consensus: none
- Target (low)
- 27.00
- Target (mean)
- 40.50
- Target (high)
- 54.00
- Strong buy2
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 28, 2024
Expected Mar 28, 2024. Consensus EPS estimate -0.70.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 8, 2024 | Sep 1, 2024 | -0.90 | -0.81 | +0.09 | +10.00% |
| Aug 9, 2024 | Jun 1, 2024 | -0.95 | -0.53 | +0.42 | +44.21% |
| May 10, 2024 | Mar 1, 2024 | 5.58 | 3.42 | -2.16 | -38.71% |
| Mar 28, 2024 | Dec 1, 2023 | -0.33 | — | — | — |
| Nov 9, 2023 | Sep 1, 2023 | -2.70 | -8.01 | -5.31 | -196.67% |
| Aug 8, 2023 | Jun 1, 2023 | -4.59 | -7.11 | -2.52 | -54.90% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 22, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 23, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| May 20, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 27, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Feb 9, 2024 | HC Wainwright & Co. | main | Buy | Buy |
About Kiora Pharmaceuticals, Inc.
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials indicated for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, currently under phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; KIO-101, an eye drop for the treatment of ocular presentation of rheumatoid arthritis; and KIO-201, an eye drop for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. It has commercialization agreement with 4SC Discovery GmbH, for KIO-101; and collaboration agreement with Théa Open Innovation for the development KIO-301. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- kiorapharma.com
News
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- Kiora Pharmaceuticals Obtains Exclusive Development And Commercialization Rights, Outside Asia, To KIO-401 From Senju Pharmaceutical For Central Retinal Artery Occlusion For $3.5M In Upfront Payment And $285M In Additional Milestones And Royalties-8K Filing
- Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
- Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
- Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
- Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway
- Financial Comparison: Cronos Group (NASDAQ:CRON) & Kiora Pharmaceuticals (NASDAQ:KPRX)
- 12 Health Care Stocks Moving In Monday's After-Market Session
Your note
Sign in to keep a note on KPRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DANIELS ERIC JOSEPH | Officer | Stock Award(Grant) | Jun 30, 2024 | 18,577 |
| PARSONS ERIN | Director | Purchase | Jun 12, 2024 | 0 |
| SHAPIRO ARON | Director | Purchase | Sep 9, 2024 | 0 |
| STENGONE CARMINE N | Director | Purchase | Sep 10, 2024 | 1,250 |
| STREM BRIAN M. | Chief Executive Officer | Stock Award(Grant) | Jun 30, 2024 | 30,160 |
| TOSCA MELISSA | Chief Financial Officer | Purchase | Aug 13, 2024 | 13,599 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Rosalind Advisors, Inc. | 8.52% | 255,555 | 840.77K | Sep 29, 2024 |
| AIGH Capital Management LLC | 8.52% | 255,555 | 840.77K | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 7.04% | 211,110 | 694.55K | Sep 29, 2024 |
| Stonepine Capital Management, LLC | 6.74% | 202,400 | 665.89K | Sep 29, 2024 |
| Adar1 Capital Management, LLC | 6.55% | 196,551 | 646.65K | Sep 29, 2024 |
| Alyeska Investment Group, L.p. | 6.02% | 180,780 | 594.77K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.45% | 13,435 | 44.20K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.09% | 2,729 | 8.98K | Sep 29, 2024 |
| Bridgeway Fds Inc-Omni Small Cap Value Fund | 0.07% | 2,000 | 6.58K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.05% | 1,413 | 4.65K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.02% | 747 | 2.46K | Oct 30, 2024 |